Emergence of VanD-type vancomycin-resistant Enterococcus faecium in Stockholm, Sweden

Clinical Microbiology and Infection

Volumn 13, Issue 1, 2007, Pages 106-108

  Fang, H ^a   Hedin, G ^a   Telander, B ^a   Li, G ^a   Nord, Carl Erik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Enterococcus faecium; Resistance; Sweden; Teicoplanin; Vancomycin; VanD

Indexed keywords

AMPICILLIN; BACTERIAL PROTEIN; CEFADROXIL; CLINDAMYCIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; NORFLOXACIN; OXACILLIN; PROTEIN VAND; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROCOCCUS FAECIUM; GENE SEQUENCE; INFECTION CONTROL; LIVER TRANSPLANTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SWEDEN; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ENTEROCOCCUS FAECIUM;

EID: 33845343274     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01569.x     Document Type: Article

References (17)

1. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-161.
2. Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; i: 57-58.
3. Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003; 51 (suppl 3): 13-21.
4. Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: Epidemiology and control. Curr Opin Infect Dis 2005; 18: 300-305.
5. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 (suppl 1): S25-S34.
6. Arthur M, Reynolds P, Courvalin P. Glycopeptide resistance in enterococci. Trends Microbiol 1996; 4: 401-407.
7. Fines M, Perichon B, Reynolds P, Sahm DF, Courvalin P. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405. Antimicrob Agents Chemother 1999; 43: 2161-2164.
8. McKessar SJ, Berry AM, Bell JM, Turnidge JD, Paton JC. Genetic characterization of vanG, a novel vancomycin resistance locus of Enterococcus faecalis. Antimicrob Agents Chemother 2000; 44: 3224-3228.
9. Depardieu F, Kolbert M, Pruul H, Bell J, Courvalin P. VanD-type vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 2004; 48: 3892-3904.
10. Lavigne JP, Marchandin H, Bouziges N, Sotto A. First infection with VanD-type glycopeptide-resistant Enterococcus faecium in Europe. J Clin Microbiol 2005; 43: 3512-3515.
11. Boyd DA, Kibsey P, Roscoe D, Mulvey MR. Enterococcus faecium N03-0072 carries a new VanD-type vancomycin resistance determinant: characterization of the VanD5 operon. J Antimicrob Chemother 2004; 54: 680-683.
12. Dalla Costa LM, Reynolds PE, Souza HA, Souza DC, Palepou MF, Woodford N. Characterization of a divergent vanD -type resistance element from the first glycopeptide-resistant strain of Enterococcus faecium isolated in Brazil. Antimicrob Agents Chemother 2000; 44: 3444-3446.
13. Ostrowsky BE, Clark NC, Thauvin-Eliopoulos C et al. A cluster of VanD vancomycin-resistant Enterococcus faecium: Molecular characterization and clinical epidemiology. J Infect Dis 1999; 180: 1177-1185.
14. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Enterococcus faecium BM4339. Antimicrob Agents Chemother 1997; 41: 2016-2018.
15. Perichon B, Casadewall B, Reynolds P, Courvalin P. Glycopeptide-resistant Enterococcus faecium BM4416 is a VanD-type strain with an impaired D -alanine: D -alanine ligase. Antimicrob Agents Chemother 2000; 44: 1346-1348.
16. Depardieu F, Perichon B, Courvalin P. Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR. J Clin Microbiol 2004; 42: 5857-5860.
17. Levine DP. Vancomycin: A history. Clin Infect Dis 2006; 42 (suppl 1): S5-S12.